BJDX · Bluejay Diagnostics, Inc.

Summary

Bluejay Diagnostics issued a corporate update on March 6, 2026, reporting financial results for the year ended December 31, 2025, including $5.2 million in cash and cash equivalents, $6.0 million in stockholders’ equity, and net losses of $6.8 million. The company highlighted progress on its Symphony platform, SYMON II clinical study, manufacturing readiness, and plans to raise at least $20 million in additional capital through 2027.

Key takeaways

• SYMON II clinical study progressing as planned with ongoing enrollment
• Manufacturing scale-up on track for regulatory submission and commercialization
• Full exercise of prefunded warrants in February 2026 resulted in approximately 972,000 common shares outstanding
• Cash and cash equivalents of $5.2 million as of December 31, 2025
• Stockholders’ equity of $6.0 million as of December 31, 2025
• Net losses of $6.8 million for fiscal year ended December 31, 2025
• Expects to raise at least $20 million through end of 2027 fiscal year